Potential of an anti-bevacizumab idiotype scFv DNA-based immunization to elicit VEGF-binding antibody response

Autor(es)

Silva, Tabata Almeida ; Aguiar, Rodrigo Barbosa ; Mori, Marcelo ; Machado, Gabriel Esquitini ; Hamaguchi, Barbara ; Machado, Marcelo Ferreira Marcondes ; Moraes, Jane Zveiter

• Tipo de documento: Artigo Científico
• Fonte: Gene Therapy; v. N/A, p. 5-pg., 2022-12-08.

Resumo

Anti-idiotype antibodies have been considered for vaccination approaches against different diseases, including cancers. Based on that, we previously described an anti-bevacizumab idiotype monoclonal antibody, 10.D7, that revealed detectable antitumor effects on a vascular endothelial growth factor (VEGF)-dependent tumor model. Herein, we evaluated the possible applicability of a single-chain variable fragment (scFv) for the 10.D7 antibody in a gene immunization strategy. After checking that mammalian cells transfected to express the 10.D7 scFv are recognized by bevacizumab, it was explored the ability of our scFv construction, in a gene-based scheme, to elicit an immune response containing VEGF-binding antibodies. The results provide evidence that the designed 10.D7 scFv construct maintains the anti-bevacizumab idiotype features and has potential to activate an immune response recognizing VEGF. (AU)

• Processo FAPESP: 16/14358-2 - Estudo do efeito do anticorpo anti-Id 10.D7 na inibição de formação de metástases e construção de vacina gênica, scFv 10.D7, que mimetiza fator de crescimento de endotélio vascular (VEGF)
• Beneficiário: Jane Zveiter de Moraes
• Modalidade de apoio: Auxílio à Pesquisa - Regular